Johnson & Johnson Total Debt Growth & History (JNJ)
Johnson & Johnson's total debt was $49.34B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $49.34B | $11.49B | +30.35% |
| 2024 | 2024-12-29 | $37.85B | $7.37B | +24.18% |
| 2023 | 2023-12-31 | $30.48B | −$10.51B | −25.63% |
| 2022 | 2023-01-01 | $40.99B | $6.20B | +17.83% |
| 2021 | 2022-01-02 | $34.78B | −$1.55B | −4.27% |
| 2020 | 2021-01-04 | $36.34B | $7.64B | +26.63% |
| 2019 | 2019-12-29 | $28.69B | −$1.79B | −5.87% |
| 2018 | 2018-12-30 | $30.48B | −$4.09B | −11.83% |
| 2017 | 2017-12-31 | $34.58B | $7.43B | +27.39% |
| 2016 | 2017-01-01 | $27.14B | $7.29B | +36.69% |
| 2015 | 2016-01-03 | $19.86B | $1.14B | +6.06% |
| 2014 | 2014-12-28 | $18.72B | $494.0M | +2.71% |
| 2013 | 2013-12-29 | $18.23B | $2.04B | +12.59% |
| 2012 | 2012-12-30 | $16.19B | −$3.48B | −17.69% |
| 2011 | 2012-01-01 | $19.67B | $2.91B | +17.38% |
| 2010 | 2011-01-02 | $16.76B | $2.18B | +14.96% |
| 2009 | 2010-01-03 | $14.57B | $2.72B | +22.98% |
| 2008 | 2008-12-28 | $11.85B | — | — |
Johnson & Johnson quarterly total debt
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $49.04B | −$1.73B | −3.40% |
| Q1 2026 | 2026-03-29 | $54.99B | $2.73B | +5.23% |
| Q4 2025 | 2025-12-28 | $49.34B | $11.49B | +30.35% |
| Q3 2025 | 2025-09-28 | $45.80B | $10.04B | +28.09% |
| Q2 2025 | 2025-06-29 | $50.76B | $9.27B | +22.34% |
| Q1 2025 | 2025-03-30 | $52.25B | $18.62B | +55.36% |
| Q4 2024 | 2024-12-29 | $37.85B | $7.37B | +24.18% |
| Q3 2024 | 2024-09-29 | $35.75B | $5.83B | +19.48% |
| Q2 2024 | 2024-06-30 | $41.49B | −$4.11B | −9.01% |
| Q1 2024 | 2024-03-31 | $33.63B | −$19.27B | −36.43% |
| Q4 2023 | 2023-12-31 | $30.48B | −$10.51B | −25.63% |
| Q3 2023 | 2023-10-01 | $29.92B | −$2.11B | −6.58% |
| Q2 2023 | 2023-07-02 | $45.60B | $13.01B | +39.90% |
| Q1 2023 | 2023-04-02 | $52.91B | $19.76B | +59.61% |
| Q4 2022 | 2023-01-01 | $40.99B | $6.20B | +17.83% |
| Q3 2022 | 2022-10-02 | $32.03B | −$1.90B | −5.60% |
| Q2 2022 | 2022-07-03 | $32.60B | −$886.0M | −2.65% |
| Q1 2022 | 2022-04-03 | $33.15B | −$465.0M | −1.38% |
| Q4 2021 | 2022-01-02 | $34.78B | — | — |
| Q3 2021 | 2021-10-03 | $33.93B | −$3.83B | −10.14% |
| Q2 2021 | 2021-07-04 | $33.48B | $3.09B | +10.16% |
| Q1 2021 | 2021-04-04 | $33.61B | $6.03B | +21.86% |
| Q4 2020 | 2021-01-04 | $36.34B | $7.64B | +26.63% |
| As of Jan 3, 2021 | 2021-01-03 | $36.34B | $7.64B | +26.63% |
| Q3 2020 | 2020-09-27 | $37.76B | $7.55B | +24.99% |
| Q2 2020 | 2020-06-28 | $30.39B | −$35.0M | −0.12% |
| Q1 2020 | 2020-03-29 | $27.58B | −$2.69B | −8.89% |
| Q4 2019 | 2019-12-29 | $28.69B | −$1.79B | −5.87% |
| Q3 2019 | 2019-09-29 | $30.21B | −$1.04B | −3.34% |
| Q2 2019 | 2019-06-30 | $30.43B | −$1.65B | −5.16% |
| Q1 2019 | 2019-03-31 | $30.27B | −$2.26B | −6.95% |
| Q4 2018 | 2018-12-30 | $30.48B | −$4.09B | −11.83% |
| Q3 2018 | 2018-09-30 | $31.25B | −$3.91B | −11.13% |
| Q2 2018 | 2018-07-01 | $32.08B | −$2.49B | −7.20% |
| Q1 2018 | 2018-04-01 | $32.53B | $163.0M | +0.50% |
| Q4 2017 | 2017-12-31 | $34.58B | $7.43B | +27.39% |
| Q3 2017 | 2017-10-01 | $35.17B | $8.18B | +30.30% |
| Q2 2017 | 2017-07-02 | $34.57B | $8.33B | +31.74% |
| Q1 2017 | 2017-04-02 | $32.37B | $9.02B | +38.64% |
| Q4 2016 | 2017-01-01 | $27.14B | $7.29B | +36.69% |
| Q3 2016 | 2016-10-02 | $26.99B | $7.24B | +36.65% |
| Q2 2016 | 2016-07-03 | $26.24B | $6.94B | +35.92% |
| Q1 2016 | 2016-04-03 | $23.35B | $4.37B | +23.00% |
| Q4 2015 | 2016-01-03 | $19.86B | $1.14B | +6.06% |
| Q3 2015 | 2015-09-27 | $19.75B | $4.48B | +29.36% |
| Q2 2015 | 2015-06-28 | $19.31B | $2.19B | +12.76% |
| Q1 2015 | 2015-03-29 | $18.98B | $1.69B | +9.78% |
| Q4 2014 | 2014-12-28 | $18.72B | $494.0M | +2.71% |
| Q3 2014 | 2014-09-28 | $15.27B | $160.0M | +1.06% |
| Q2 2014 | 2014-06-29 | $17.12B | $2.14B | +14.28% |
| Q1 2014 | 2014-03-30 | $17.29B | $1.40B | +8.81% |
| Q4 2013 | 2013-12-29 | $18.23B | $2.04B | +12.59% |
| Q3 2013 | 2013-09-29 | $15.11B | −$1.74B | −10.35% |
| Q2 2013 | 2013-06-30 | $14.98B | −$2.58B | −14.71% |
| Q1 2013 | 2013-03-31 | $15.89B | −$3.56B | −18.29% |
| Q4 2012 | 2012-12-30 | $16.19B | −$3.48B | −17.69% |
| Q3 2012 | 2012-09-30 | $16.85B | −$1.51B | −8.20% |
| Q2 2012 | 2012-07-01 | $17.57B | −$1.16B | −6.20% |
| Q1 2012 | 2012-04-01 | $19.45B | $1.62B | +9.08% |
| Q4 2011 | 2012-01-01 | $19.67B | $2.91B | +17.38% |
| Q3 2011 | 2011-10-02 | $18.36B | $6.33B | +52.66% |
| Q2 2011 | 2011-07-03 | $18.73B | $7.07B | +60.71% |
| Q1 2011 | 2011-04-03 | $17.83B | $5.73B | +47.32% |
| Q4 2010 | 2011-01-02 | $16.76B | $2.18B | +14.96% |
| Q3 2010 | 2010-10-03 | $12.03B | $425.0M | +3.66% |
| Q2 2010 | 2010-07-04 | $11.65B | −$1.96B | −14.41% |
| Q1 2010 | 2010-04-04 | $12.10B | — | — |
| Q4 2009 | 2010-01-03 | $14.57B | $2.72B | +22.98% |
| Q3 2009 | 2009-09-27 | $11.60B | — | — |
| Q2 2009 | 2009-06-28 | $13.61B | — | — |
| Q4 2008 | 2008-12-28 | $11.85B | — | — |
Johnson & Johnson total debt trends
Over the last five fiscal years, Johnson & Johnson's total debt increased from $36.34B to $49.34B, a change of $13.00B. The latest reported quarter, Q2 2026, shows $49.04B.
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...